Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEND: 3-Year Virologic Follow-up After Telaprevir
2009-011464-11Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telaprevir in hepatitis C virus infection, sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term virologic outcomes. Started Jul 2009; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-011464-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011464-11.